Search | Clinical Trials Finder

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 23
States / cities: Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more

Conditions: Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Acute and Progressive, Clinically Isolated Syndrome, CNS Demyelinating
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 30 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 59 more

Conditions: Migraine Disorders
Interventions: Sumatriptan succinate, NP101 Study Patch; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Hallandale, Florida

Conditions: Parkinson Disease
Interventions: N-0923; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania

Conditions: Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol; Drug · Diagnostic Test
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • The Woodlands, Texas

Conditions: Brain Tumors
Interventions: 5-aminolevulinic acid; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Brain Tumors
Interventions: 5-aminolevulinic acid; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Epilepsy
Interventions: Observational only, Psychological and Behavioral interaction with a seizure forecasting mobile app, Seizure Alerting and Prediction System; Device · Behavioral · Combination Product
Lead sponsor: Epitel, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York

Conditions: HIV Infections, Lymphoma, AIDS-Related
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 20 Years to 59 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Visual Field Defect, Stroke, Hemianopia, Quadrantanopia, Cortical Blindness, Brain Tumor, Traumatic Brain Injury, Visual Field Defect, Peripheral
Interventions: transcranial random noise stimulation (tRNS), Sham Stimulation, Perceptual learning-based training; Device · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: VAY736, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Long Beach, California • San Diego, California

Conditions: Brain Tumor, Brain Cancer, Motor Cortex; Lesion
Interventions: Intraoperative Brain Simulation - Alternate Stimulation Parameters; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Amblyopia, Binocular Vision Disorder
Interventions: Binocular cartoon treatment at home, Patching, Binocular cartoon treatment in office; Other
Lead sponsor: University of Waterloo; Other
Eligibility: 36 Months to 83 Months
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Heart Failure, Vascular Ischemia, Burns, Chemotherapy Effect, Radiation Injuries, Uveitis, Scleritis, Multiple Sclerosis, Autonomic Neuropathy, Stroke, Intracranial Hemorrhages, TIA, Migraine, Headache, Pain
Interventions: laser speckle flowgraphy; Device
Lead sponsor: Randy Kardon; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Traumatic Brain Injury, Cognitive Impairment
Interventions: Rivastigmine Transdermal Patch; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 8
States / cities: San Diego, California • Miami, Florida • Tampa, Florida + 5 more

Conditions: Multiple Sclerosis
Interventions: tolebrutinib 60mg, tolebrutinib 120mg; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tetraplegia, Hypothermia, Mild Cognitive Impairment
Interventions: Warm Temperature; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 68 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atrial Fibrillation
Interventions: iRhythm ZIO XT Patch, Wristband by Amiigo; Device
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 55 Years and older
Enrollment: 6,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Adult Brain Tumor, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Melanocytic Lesion, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma, Adult Pineocytoma, Recurrent Adult Brain Tumor
Interventions: proton beam radiation therapy, quality-of-life assessment, questionnaire administration; Radiation · Procedure · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Spinal Cord Neoplasm
Interventions: Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Device · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Treatment of Parkinson's Disease With a Transdermal Skin Patch

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

ALA-induced PpIX Fluorescence During Brain Tumor Resection

Fluorescence Guided Resection of Brain Tumors

A Wireless EEG Patch for Continuous Electrographic Monitoring

Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors

A Patch Free Treatment for Young Children With Amblyopia

LSFG-SKIN, Laser Speckle Flowgraphy

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Effect of Heat Exposure on Cognition in Persons With Tetraplegia

mHealth Screening to Prevent Strokes

Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.